If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 425.00
Bid: 420.00
Ask: 430.00
Change: 7.50 (1.80%)
Spread: 10.00 (2.381%)
Open: 417.50
High: 425.00
Low: 417.50
Prev. Close: 417.50
AVG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Superconducting Magnet Business

28 Feb 2017 07:00

RNS Number : 9880X
Avingtrans PLC
28 February 2017
 

28 February 2017

 

Avingtrans Plc

("Avingtrans", the "Company" or the "Group")

 

Avingtrans Acquires Superconducting Magnet Business

 

Avingtrans PLC is pleased to announce the acquisition of a majority stake in superconducting magnet and cryogenic systems company Space Cryomagnetics Limited, trading as 'Scientific Magnetics' (the "Acquisition") for total consideration of £347k.

 

Scientific Magnetics, based in Abingdon, Oxford with 15 members of staff, was formed in 2000 as a spin-out from Oxford Instruments, before becoming fully independent in 2005. It designs, manufactures, tests and installs superconducting magnet systems for a range of applications, as well as providing consultancy services to blue chip companies, such as Siemens and Rolls-Royce.

 

The Acquisition will bring Scientific Magnetics' expertise in superconducting magnets and cryogenics together with the Company's own engineering and volume production division, which also has a long track record of innovation in the medical and space sectors. In addition, Scientific Magnetics will broaden the Group's capability in the supply of vacuum vessels and cryostats for Big Science, space and astronomy projects. Scientific Magnetics has recently developed a number of exciting technologies, including a helium-free magnet system for pre-clinical MRI and ultra-high vacuum (UHV) applications, and the Directors believe that the Acquisition will enable Scientific Magnetics to bridge the gap between prototype development and commercial production; a proven area of expertise for Avingtrans.

 

Steve McQuillan, CEO of Avingtans, commented:

"We are delighted to have completed this deal, which will deliver a real step change in our offer to several key markets.

 

"The Acquisition aligns with our 'buy and build' strategy, which also saw us purchase the assets of oil & gas manufacturer Whiteley Read in December 2016. We are looking forward to working with the Scientific Magnetics team to deliver on what are genuinely exciting opportunities across a number of key markets."

 

Consideration for the Acquisition is £347k (the "Consideration"), payable by way of £285k in cash and £62k to be satisfied by the issue of 27,233 new ordinary shares in the capital of Avingtrans (the "Consideration Shares"), in exchange for 94 per cent. of the issued share capital of Scientific Magnets. The Consideration Shares are to be issued at a price of 226.5p per share, being the average mid-market closing price of the Company over the five trading days prior to signing the share purchase agreement in respect of the Acquisition. As part of the Acquisition the Company has also agreed to repay an outstanding loan and accrued interest owed by Scientific Magnets, amounting to approximately £468k.

 

For the year ended 30 June 2016, Scientific Magnetics reported turnover of £2.0m and profit before taxation of £41k.

 

Application will be made for the Consideration Shares to be admitted to trading on AIM, with such admission expected to take place on 6 March 2016 ("Admission"). Following Admission, the Company's total issued share capital will be 19,171,123 Ordinary Shares. Avingtrans does not hold any Ordinary Shares in treasury and therefore following Admission, the total number of voting rights in Avingtrans will be 19,171,123.

 

The above figure 19,171,123 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Avingtrans under the FSA's Disclosure Guidance and Transparency Rules. 

 

Enquiries:

Avingtrans plc

Steve McQuillan, CEO

Stephen King, CFO 

 

0135 469 2391

N+1 Singer

Shaun Dobson

Lauren Kettle

 

020 7496 3000

Newgate (Financial PR)Adam LloydEd Treadwell

James Browne

020 7653 9850

 

About Avingtrans

 

Avingtrans plc is engaged in the provision of highly engineered components, systems and services to the energy, medical and traffic management industries worldwide. 

 

Energy and medical, engaged in the design and manufacture of safety critical equipment for the energy, medical, science and research communities, including oil and gas extraction and processing equipment, nuclear process plant, machined and fabricated pressure and vacuum vessels and components. Also, design and manufacture of fabricated poles and cabinets for roadside safety cameras and rail track signalling.

 

The strategy of the group, is to "buy and build" in regulated engineering niche markets, where we can see potential consolidation opportunities, which can lead to significantly increased shareholder value over the medium to long term.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQTRMPTMBMTBTR
Date   Source Headline
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor
22nd Nov 20237:00 amRNSEmployee & PDMR Share Incentive Awards
16th Nov 20232:20 pmRNSResult of AGM
13th Nov 20237:00 amRNSHayward Tyler Contract Win
11th Oct 20237:00 amRNSContract Wins
28th Sep 20235:54 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSPreliminary results for the year ended 31 May 2023
25th Sep 20237:00 amRNSHolding(s) in Company
18th Sep 20237:00 amRNSCompletion of Acquisition of Adaptix Ltd
4th Sep 20237:00 amRNSBoard Update
7th Aug 20237:00 amRNSAcquisition of Slack & Parr and Adaptix update
13th Jul 20237:00 amRNSTrading Update & Possible Acquisition of Adaptix
5th Jun 20237:00 amRNSBoard Changes
22nd Feb 20237:00 amRNSInterim Results
15th Feb 20237:00 amRNSAdaptix appoints Willem Baralt as new Chairman
30th Jan 20237:00 amRNSAdaptix secures 510(k) clearance from FDA
27th Jan 20231:19 pmRNSEmployee & PDMR Share Incentive Awards
23rd Jan 20236:12 pmRNSPDMR Dealings
18th Jan 20237:00 amRNSAdditional Investment in Magnetica
16th Jan 20237:00 amRNSTrading Update, Acquisitions and Notice of Results
23rd Dec 20228:30 amRNSExercise of Options, PDMR Dealings & TVR
14th Dec 20227:00 amRNSSteve McQuillan appointed as Chairman of Adaptix
17th Nov 20223:56 pmRNSResult of Annual General Meeting
28th Sep 20227:00 amRNSPreliminary results for the year ended 31 May 2022
27th Jul 20222:38 pmRNSHolding(s) in Company
7th Jul 20227:00 amRNSTrading Update and Notice of Results
11th Apr 20227:00 amRNSHayward Tyler Secures Nuclear Contracts worth $7m
6th Apr 202212:59 pmRNSExercise of Options and Total Voting Rights
29th Mar 20225:13 pmRNSPDMR Dealing
21st Mar 20227:00 amRNSEnergy Steel Secures Nuclear Contract worth $4.1m
17th Mar 20227:00 amRNSContract Wins
23rd Feb 20227:00 amRNSDirectorate Change
23rd Feb 20227:00 amRNSInterim Results
20th Jan 20227:00 amRNSTrading Update, Notice of Results and Investment
29th Nov 20215:57 pmRNSEmployee & PDMR Share Incentive Awards
22nd Nov 20212:32 pmRNSExercise of Options, PDMR Dealings and TVR
18th Nov 202112:41 pmRNSResult of AGM
13th Oct 20217:00 amRNSInvestment in emerging medtech leader, Adaptix
29th Sep 20217:00 amRNSPreliminary Results for the year ended 31 May 2021
12th Aug 202112:20 pmRNSExercise of Options and Total Voting Rights
12th Jul 202110:51 amRNSExercise of Options, PDMR Dealings and TVR
12th Jul 20217:00 amRNSAvingtrans’ businesses nuclear contract
8th Jul 20217:00 amRNSTrading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.